{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T02:12:26Z","timestamp":1791252746832,"version":"4.1.0"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Hypertension"],"published-print":{"date-parts":[[2011,11]]},"abstract":"<jats:p>\n                    To assess whether angiotensin-converting enzyme inhibitors and third-generation dihydropyridine calcium channel blockers ameliorate diabetic complications, we compared glomerular filtration rate (GFR; primary outcome), cardiovascular events, retinopathy, and neuropathy in 380 hypertensive type 2 diabetics with albuminuria &lt;200 mg\/min included in a multicenter, double-blind, placebo-controlled trial (DEMAND [Delapril and Manidipine for Nephroprotection in Diabetes]) and randomized to 3-year treatment with manidipine\/delapril combination (10\/30 mg\/d; n=126), delapril (30 mg\/d; n=127), or placebo (n=127). GFR was centrally measured by iohexol plasma clearance. Median monthly GFR decline (interquartile range [IQR]) was 0.32 mL\/min per 1.73 m\n                    <jats:sup>2<\/jats:sup>\n                    (IQR: 0.16\u20130.50 mL\/min per 1.73 m\n                    <jats:sup>2<\/jats:sup>\n                    ) on combined therapy, 0.36 mL\/min per 1.73 m\n                    <jats:sup>2<\/jats:sup>\n                    (IQR: 0.18\u20130.53 mL\/min per 1.73 m\n                    <jats:sup>2<\/jats:sup>\n                    ) on delapril, and 0.30 mL\/min per 1.73 m\n                    <jats:sup>2<\/jats:sup>\n                    (IQR: 0.12\u20130.50 mL\/min per 1.73 m\n                    <jats:sup>2<\/jats:sup>\n                    ) on placebo (\n                    <jats:italic>P<\/jats:italic>\n                    =0.87 and\n                    <jats:italic>P<\/jats:italic>\n                    =0.53 versus combined therapy or delapril, respectively). Similar findings were observed when baseline GFR values were not considered for slope analyses. Albuminuria was stable in the 3 treatment groups. The hazard ratio (95% CI) for major cardiovascular events between combined therapy and placebo was 0.17 (0.04\u20130.78;\n                    <jats:italic>P<\/jats:italic>\n                    =0.023). Among 192 subjects without retinopathy at inclusion, the hazard ratio for developing retinopathy between combined therapy and placebo was 0.27 (0.07\u20130.99;\n                    <jats:italic>P<\/jats:italic>\n                    =0.048). Among 200 subjects with centralized neurological evaluation, the odds ratios for peripheral neuropathy at 3 years between combined therapy or delapril and placebo were 0.45 (0.24\u20130.87;\n                    <jats:italic>P<\/jats:italic>\n                    =0.017) and 0.52 (0.27\u20130.99;\n                    <jats:italic>P<\/jats:italic>\n                    =0.048), respectively. Glucose disposal rate decreased from 5.8\u00b12.4 to 5.3\u00b11.9 mg\/kg per min on placebo (\n                    <jats:italic>P<\/jats:italic>\n                    =0.03) but did not change on combined or delapril therapy. Treatment was well tolerated. In hypertensive type 2 diabetic patients, combined manidipine and delapril therapy failed to slow GFR decline but safely ameliorated cardiovascular disease, retinopathy, and neuropathy and stabilized insulin sensitivity.\n                  <\/jats:p>","DOI":"10.1161\/hypertensionaha.111.174474","type":"journal-article","created":{"date-parts":[[2011,9,20]],"date-time":"2011-09-20T04:40:48Z","timestamp":1316493648000},"page":"776-783","update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":95,"title":["Effects of Manidipine and Delapril in Hypertensive Patients With Type 2 Diabetes Mellitus"],"prefix":"10.1161","volume":"58","author":[{"given":"Piero","family":"Ruggenenti","sequence":"first","affiliation":[{"name":"From the Mario Negri Institute for Pharmacological Research (P.R., I.P.I., A.F., A.P.I., S.R., C.C., N.R., G.N., N.M., B.E.-I., F.G., A.P., G.R.), Clinical Research Center for Rare Diseases \u201cAldo e Cele Dacc\u00f2,\u201d Ranica, Bergamo, Italy; Unit of Nephrology (P.R., S.R., G.R.), Azienda Ospedaliera Ospedali Riuniti di Bergamo, Bergamo, Italy; Neuromuscular Diseases Unit (G.L., A.S., R.L., P.P.), Istituto Di Ricovero e Cura a Carattere Scientifico Foundation \u201cCarlo Besta\u201d Neurological Institute, Milan,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Lauria","sequence":"additional","affiliation":[{"name":"From the Mario Negri Institute for Pharmacological Research (P.R., I.P.I., A.F., A.P.I., S.R., C.C., N.R., G.N., N.M., B.E.-I., F.G., A.P., G.R.), Clinical Research Center for Rare Diseases \u201cAldo e Cele Dacc\u00f2,\u201d Ranica, Bergamo, Italy; Unit of Nephrology (P.R., S.R., G.R.), Azienda Ospedaliera Ospedali Riuniti di Bergamo, Bergamo, Italy; Neuromuscular Diseases Unit (G.L., A.S., R.L., P.P.), Istituto Di Ricovero e Cura a Carattere Scientifico Foundation \u201cCarlo Besta\u201d Neurological Institute, Milan,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilian Petrov","family":"Iliev","sequence":"additional","affiliation":[{"name":"From the Mario Negri Institute for Pharmacological Research (P.R., I.P.I., A.F., A.P.I., S.R., C.C., N.R., G.N., N.M., B.E.-I., F.G., A.P., G.R.), Clinical Research Center for Rare Diseases \u201cAldo e Cele Dacc\u00f2,\u201d Ranica, Bergamo, Italy; Unit of Nephrology (P.R., S.R., G.R.), Azienda Ospedaliera Ospedali Riuniti di Bergamo, Bergamo, Italy; Neuromuscular Diseases Unit (G.L., A.S., R.L., P.P.), Istituto Di Ricovero e Cura a Carattere Scientifico Foundation \u201cCarlo Besta\u201d Neurological Institute, Milan,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Fassi","sequence":"additional","affiliation":[{"name":"From the Mario Negri Institute for Pharmacological Research (P.R., I.P.I., A.F., A.P.I., S.R., C.C., N.R., G.N., N.M., B.E.-I., F.G., A.P., G.R.), Clinical Research Center for Rare Diseases \u201cAldo e Cele Dacc\u00f2,\u201d Ranica, Bergamo, Italy; Unit of Nephrology (P.R., S.R., G.R.), Azienda Ospedaliera Ospedali Riuniti di Bergamo, Bergamo, Italy; Neuromuscular Diseases Unit (G.L., A.S., R.L., P.P.), Istituto Di Ricovero e Cura a Carattere Scientifico Foundation \u201cCarlo Besta\u201d Neurological Institute, Milan,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aneliya Parvanova","family":"Ilieva","sequence":"additional","affiliation":[{"name":"From the Mario Negri Institute for Pharmacological Research (P.R., I.P.I., A.F., A.P.I., S.R., C.C., N.R., G.N., N.M., B.E.-I., F.G., A.P., G.R.), Clinical Research Center for Rare Diseases \u201cAldo e Cele Dacc\u00f2,\u201d Ranica, Bergamo, Italy; Unit of Nephrology (P.R., S.R., G.R.), Azienda Ospedaliera Ospedali Riuniti di Bergamo, Bergamo, Italy; Neuromuscular Diseases Unit (G.L., A.S., R.L., P.P.), Istituto Di Ricovero e Cura a Carattere Scientifico Foundation \u201cCarlo Besta\u201d Neurological Institute, Milan,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Rota","sequence":"additional","affiliation":[{"name":"From the Mario Negri Institute for Pharmacological Research (P.R., I.P.I., A.F., A.P.I., S.R., C.C., N.R., G.N., N.M., B.E.-I., F.G., A.P., G.R.), Clinical Research Center for Rare Diseases \u201cAldo e Cele Dacc\u00f2,\u201d Ranica, Bergamo, Italy; Unit of Nephrology (P.R., S.R., G.R.), Azienda Ospedaliera Ospedali Riuniti di Bergamo, Bergamo, Italy; Neuromuscular Diseases Unit (G.L., A.S., R.L., P.P.), Istituto Di Ricovero e Cura a Carattere Scientifico Foundation \u201cCarlo Besta\u201d Neurological Institute, Milan,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Chiurchiu","sequence":"additional","affiliation":[{"name":"From the Mario Negri Institute for Pharmacological Research (P.R., I.P.I., A.F., A.P.I., S.R., C.C., N.R., G.N., N.M., B.E.-I., F.G., A.P., G.R.), Clinical Research Center for Rare Diseases \u201cAldo e Cele Dacc\u00f2,\u201d Ranica, Bergamo, Italy; Unit of Nephrology (P.R., S.R., G.R.), Azienda Ospedaliera Ospedali Riuniti di Bergamo, Bergamo, Italy; Neuromuscular Diseases Unit (G.L., A.S., R.L., P.P.), Istituto Di Ricovero e Cura a Carattere Scientifico Foundation \u201cCarlo Besta\u201d Neurological Institute, Milan,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Drazenka Pongrac","family":"Barlovic","sequence":"additional","affiliation":[{"name":"From the Mario Negri Institute for Pharmacological Research (P.R., I.P.I., A.F., A.P.I., S.R., C.C., N.R., G.N., N.M., B.E.-I., F.G., A.P., G.R.), Clinical Research Center for Rare Diseases \u201cAldo e Cele Dacc\u00f2,\u201d Ranica, Bergamo, Italy; Unit of Nephrology (P.R., S.R., G.R.), Azienda Ospedaliera Ospedali Riuniti di Bergamo, Bergamo, Italy; Neuromuscular Diseases Unit (G.L., A.S., R.L., P.P.), Istituto Di Ricovero e Cura a Carattere Scientifico Foundation \u201cCarlo Besta\u201d Neurological Institute, Milan,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Sghirlanzoni","sequence":"additional","affiliation":[{"name":"From the Mario Negri Institute for Pharmacological Research (P.R., I.P.I., A.F., A.P.I., S.R., C.C., N.R., G.N., N.M., B.E.-I., F.G., A.P., G.R.), Clinical Research Center for Rare Diseases \u201cAldo e Cele Dacc\u00f2,\u201d Ranica, Bergamo, Italy; Unit of Nephrology (P.R., S.R., G.R.), Azienda Ospedaliera Ospedali Riuniti di Bergamo, Bergamo, Italy; Neuromuscular Diseases Unit (G.L., A.S., R.L., P.P.), Istituto Di Ricovero e Cura a Carattere Scientifico Foundation \u201cCarlo Besta\u201d Neurological Institute, Milan,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaella","family":"Lombardi","sequence":"additional","affiliation":[{"name":"From the Mario Negri Institute for Pharmacological Research (P.R., I.P.I., A.F., A.P.I., S.R., C.C., N.R., G.N., N.M., B.E.-I., F.G., A.P., G.R.), Clinical Research Center for Rare Diseases \u201cAldo e Cele Dacc\u00f2,\u201d Ranica, Bergamo, Italy; Unit of Nephrology (P.R., S.R., G.R.), Azienda Ospedaliera Ospedali Riuniti di Bergamo, Bergamo, Italy; Neuromuscular Diseases Unit (G.L., A.S., R.L., P.P.), Istituto Di Ricovero e Cura a Carattere Scientifico Foundation \u201cCarlo Besta\u201d Neurological Institute, Milan,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Penza","sequence":"additional","affiliation":[{"name":"From the Mario Negri Institute for Pharmacological Research (P.R., I.P.I., A.F., A.P.I., S.R., C.C., N.R., G.N., N.M., B.E.-I., F.G., A.P., G.R.), Clinical Research Center for Rare Diseases \u201cAldo e Cele Dacc\u00f2,\u201d Ranica, Bergamo, Italy; Unit of Nephrology (P.R., S.R., G.R.), Azienda Ospedaliera Ospedali Riuniti di Bergamo, Bergamo, Italy; Neuromuscular Diseases Unit (G.L., A.S., R.L., P.P.), Istituto Di Ricovero e Cura a Carattere Scientifico Foundation \u201cCarlo Besta\u201d Neurological Institute, Milan,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Cavaletti","sequence":"additional","affiliation":[{"name":"From the Mario Negri Institute for Pharmacological Research (P.R., I.P.I., A.F., A.P.I., S.R., C.C., N.R., G.N., N.M., B.E.-I., F.G., A.P., G.R.), Clinical Research Center for Rare Diseases \u201cAldo e Cele Dacc\u00f2,\u201d Ranica, Bergamo, Italy; Unit of Nephrology (P.R., S.R., G.R.), Azienda Ospedaliera Ospedali Riuniti di Bergamo, Bergamo, Italy; Neuromuscular Diseases Unit (G.L., A.S., R.L., P.P.), Istituto Di Ricovero e Cura a Carattere Scientifico Foundation \u201cCarlo Besta\u201d Neurological Institute, Milan,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Luisa","family":"Piatti","sequence":"additional","affiliation":[{"name":"From the Mario Negri Institute for Pharmacological Research (P.R., I.P.I., A.F., A.P.I., S.R., C.C., N.R., G.N., N.M., B.E.-I., F.G., A.P., G.R.), Clinical Research Center for Rare Diseases \u201cAldo e Cele Dacc\u00f2,\u201d Ranica, Bergamo, Italy; Unit of Nephrology (P.R., S.R., G.R.), Azienda Ospedaliera Ospedali Riuniti di Bergamo, Bergamo, Italy; Neuromuscular Diseases Unit (G.L., A.S., R.L., P.P.), Istituto Di Ricovero e Cura a Carattere Scientifico Foundation \u201cCarlo Besta\u201d Neurological Institute, Milan,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Frigeni","sequence":"additional","affiliation":[{"name":"From the Mario Negri Institute for Pharmacological Research (P.R., I.P.I., A.F., A.P.I., S.R., C.C., N.R., G.N., N.M., B.E.-I., F.G., A.P., G.R.), Clinical Research Center for Rare Diseases \u201cAldo e Cele Dacc\u00f2,\u201d Ranica, Bergamo, Italy; Unit of Nephrology (P.R., S.R., G.R.), Azienda Ospedaliera Ospedali Riuniti di Bergamo, Bergamo, Italy; Neuromuscular Diseases Unit (G.L., A.S., R.L., P.P.), Istituto Di Ricovero e Cura a Carattere Scientifico Foundation \u201cCarlo Besta\u201d Neurological Institute, Milan,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Filipponi","sequence":"additional","affiliation":[{"name":"From the Mario Negri Institute for Pharmacological Research (P.R., I.P.I., A.F., A.P.I., S.R., C.C., N.R., G.N., N.M., B.E.-I., F.G., A.P., G.R.), Clinical Research Center for Rare Diseases \u201cAldo e Cele Dacc\u00f2,\u201d Ranica, Bergamo, Italy; Unit of Nephrology (P.R., S.R., G.R.), Azienda Ospedaliera Ospedali Riuniti di Bergamo, Bergamo, Italy; Neuromuscular Diseases Unit (G.L., A.S., R.L., P.P.), Istituto Di Ricovero e Cura a Carattere Scientifico Foundation \u201cCarlo Besta\u201d Neurological Institute, Milan,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Rubis","sequence":"additional","affiliation":[{"name":"From the Mario Negri Institute for Pharmacological Research (P.R., I.P.I., A.F., A.P.I., S.R., C.C., N.R., G.N., N.M., B.E.-I., F.G., A.P., G.R.), Clinical Research Center for Rare Diseases \u201cAldo e Cele Dacc\u00f2,\u201d Ranica, Bergamo, Italy; Unit of Nephrology (P.R., S.R., G.R.), Azienda Ospedaliera Ospedali Riuniti di Bergamo, Bergamo, Italy; Neuromuscular Diseases Unit (G.L., A.S., R.L., P.P.), Istituto Di Ricovero e Cura a Carattere Scientifico Foundation \u201cCarlo Besta\u201d Neurological Institute, Milan,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greta","family":"Noris","sequence":"additional","affiliation":[{"name":"From the Mario Negri Institute for Pharmacological Research (P.R., I.P.I., A.F., A.P.I., S.R., C.C., N.R., G.N., N.M., B.E.-I., F.G., A.P., G.R.), Clinical Research Center for Rare Diseases \u201cAldo e Cele Dacc\u00f2,\u201d Ranica, Bergamo, Italy; Unit of Nephrology (P.R., S.R., G.R.), Azienda Ospedaliera Ospedali Riuniti di Bergamo, Bergamo, Italy; Neuromuscular Diseases Unit (G.L., A.S., R.L., P.P.), Istituto Di Ricovero e Cura a Carattere Scientifico Foundation \u201cCarlo Besta\u201d Neurological Institute, Milan,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Motterlini","sequence":"additional","affiliation":[{"name":"From the Mario Negri Institute for Pharmacological Research (P.R., I.P.I., A.F., A.P.I., S.R., C.C., N.R., G.N., N.M., B.E.-I., F.G., A.P., G.R.), Clinical Research Center for Rare Diseases \u201cAldo e Cele Dacc\u00f2,\u201d Ranica, Bergamo, Italy; Unit of Nephrology (P.R., S.R., G.R.), Azienda Ospedaliera Ospedali Riuniti di Bergamo, Bergamo, Italy; Neuromuscular Diseases Unit (G.L., A.S., R.L., P.P.), Istituto Di Ricovero e Cura a Carattere Scientifico Foundation \u201cCarlo Besta\u201d Neurological Institute, Milan,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bogdan","family":"Ene-Iordache","sequence":"additional","affiliation":[{"name":"From the Mario Negri Institute for Pharmacological Research (P.R., I.P.I., A.F., A.P.I., S.R., C.C., N.R., G.N., N.M., B.E.-I., F.G., A.P., G.R.), Clinical Research Center for Rare Diseases \u201cAldo e Cele Dacc\u00f2,\u201d Ranica, Bergamo, Italy; Unit of Nephrology (P.R., S.R., G.R.), Azienda Ospedaliera Ospedali Riuniti di Bergamo, Bergamo, Italy; Neuromuscular Diseases Unit (G.L., A.S., R.L., P.P.), Istituto Di Ricovero e Cura a Carattere Scientifico Foundation \u201cCarlo Besta\u201d Neurological Institute, Milan,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavio","family":"Gaspari","sequence":"additional","affiliation":[{"name":"From the Mario Negri Institute for Pharmacological Research (P.R., I.P.I., A.F., A.P.I., S.R., C.C., N.R., G.N., N.M., B.E.-I., F.G., A.P., G.R.), Clinical Research Center for Rare Diseases \u201cAldo e Cele Dacc\u00f2,\u201d Ranica, Bergamo, Italy; Unit of Nephrology (P.R., S.R., G.R.), Azienda Ospedaliera Ospedali Riuniti di Bergamo, Bergamo, Italy; Neuromuscular Diseases Unit (G.L., A.S., R.L., P.P.), Istituto Di Ricovero e Cura a Carattere Scientifico Foundation \u201cCarlo Besta\u201d Neurological Institute, Milan,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Perna","sequence":"additional","affiliation":[{"name":"From the Mario Negri Institute for Pharmacological Research (P.R., I.P.I., A.F., A.P.I., S.R., C.C., N.R., G.N., N.M., B.E.-I., F.G., A.P., G.R.), Clinical Research Center for Rare Diseases \u201cAldo e Cele Dacc\u00f2,\u201d Ranica, Bergamo, Italy; Unit of Nephrology (P.R., S.R., G.R.), Azienda Ospedaliera Ospedali Riuniti di Bergamo, Bergamo, Italy; Neuromuscular Diseases Unit (G.L., A.S., R.L., P.P.), Istituto Di Ricovero e Cura a Carattere Scientifico Foundation \u201cCarlo Besta\u201d Neurological Institute, Milan,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelka","family":"Zaletel","sequence":"additional","affiliation":[{"name":"From the Mario Negri Institute for Pharmacological Research (P.R., I.P.I., A.F., A.P.I., S.R., C.C., N.R., G.N., N.M., B.E.-I., F.G., A.P., G.R.), Clinical Research Center for Rare Diseases \u201cAldo e Cele Dacc\u00f2,\u201d Ranica, Bergamo, Italy; Unit of Nephrology (P.R., S.R., G.R.), Azienda Ospedaliera Ospedali Riuniti di Bergamo, Bergamo, Italy; Neuromuscular Diseases Unit (G.L., A.S., R.L., P.P.), Istituto Di Ricovero e Cura a Carattere Scientifico Foundation \u201cCarlo Besta\u201d Neurological Institute, Milan,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Bossi","sequence":"additional","affiliation":[{"name":"From the Mario Negri Institute for Pharmacological Research (P.R., I.P.I., A.F., A.P.I., S.R., C.C., N.R., G.N., N.M., B.E.-I., F.G., A.P., G.R.), Clinical Research Center for Rare Diseases \u201cAldo e Cele Dacc\u00f2,\u201d Ranica, Bergamo, Italy; Unit of Nephrology (P.R., S.R., G.R.), Azienda Ospedaliera Ospedali Riuniti di Bergamo, Bergamo, Italy; Neuromuscular Diseases Unit (G.L., A.S., R.L., P.P.), Istituto Di Ricovero e Cura a Carattere Scientifico Foundation \u201cCarlo Besta\u201d Neurological Institute, Milan,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro Roberto","family":"Dodesini","sequence":"additional","affiliation":[{"name":"From the Mario Negri Institute for Pharmacological Research (P.R., I.P.I., A.F., A.P.I., S.R., C.C., N.R., G.N., N.M., B.E.-I., F.G., A.P., G.R.), Clinical Research Center for Rare Diseases \u201cAldo e Cele Dacc\u00f2,\u201d Ranica, Bergamo, Italy; Unit of Nephrology (P.R., S.R., G.R.), Azienda Ospedaliera Ospedali Riuniti di Bergamo, Bergamo, Italy; Neuromuscular Diseases Unit (G.L., A.S., R.L., P.P.), Istituto Di Ricovero e Cura a Carattere Scientifico Foundation \u201cCarlo Besta\u201d Neurological Institute, Milan,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Trevisan","sequence":"additional","affiliation":[{"name":"From the Mario Negri Institute for Pharmacological Research (P.R., I.P.I., A.F., A.P.I., S.R., C.C., N.R., G.N., N.M., B.E.-I., F.G., A.P., G.R.), Clinical Research Center for Rare Diseases \u201cAldo e Cele Dacc\u00f2,\u201d Ranica, Bergamo, Italy; Unit of Nephrology (P.R., S.R., G.R.), Azienda Ospedaliera Ospedali Riuniti di Bergamo, Bergamo, Italy; Neuromuscular Diseases Unit (G.L., A.S., R.L., P.P.), Istituto Di Ricovero e Cura a Carattere Scientifico Foundation \u201cCarlo Besta\u201d Neurological Institute, Milan,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Remuzzi","sequence":"additional","affiliation":[{"name":"From the Mario Negri Institute for Pharmacological Research (P.R., I.P.I., A.F., A.P.I., S.R., C.C., N.R., G.N., N.M., B.E.-I., F.G., A.P., G.R.), Clinical Research Center for Rare Diseases \u201cAldo e Cele Dacc\u00f2,\u201d Ranica, Bergamo, Italy; Unit of Nephrology (P.R., S.R., G.R.), Azienda Ospedaliera Ospedali Riuniti di Bergamo, Bergamo, Italy; Neuromuscular Diseases Unit (G.L., A.S., R.L., P.P.), Istituto Di Ricovero e Cura a Carattere Scientifico Foundation \u201cCarlo Besta\u201d Neurological Institute, Milan,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the DEMAND Study Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)12323-7"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa042167"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011489"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011161"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61411-7"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.55.02.06.db05-0885"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)02478-7"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1159\/000072054"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF03256573"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-005-0961-2"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjhyper.2007.05.012"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1197\/jamia.M2787"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.53.8.1660"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.V62257"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-032076"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(03)00475-5"},{"key":"e_1_3_4_18_2","first-page":"S150","article-title":"Renal protective effects of enalapril in hypertensive NIDDM: role of baseline albuminuria","volume":"45","author":"Lebovitz HE","year":"1994","unstructured":"Lebovitz HE, Wiegmann TB, Cnaan A, Shahinfar S, Sica DA, Broadstone V, Schwartz SL, Mengel MC, Segal R, Versaggi JA, Bolton WK. Renal protective effects of enalapril in hypertensive NIDDM: role of baseline albuminuria. Kidney Int. 1994;45(suppl):S150\u2013S155.","journal-title":"Kidney Int"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)04433-X"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.26.12.3296"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(91)90069-X"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.1985.tb07117.x"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2008.10.037"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ki.5001729"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0808400"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2009.109"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0806182"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.281.14.1291"}],"container-title":["Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/HYPERTENSIONAHA.111.174474","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T05:49:47Z","timestamp":1715579387000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/HYPERTENSIONAHA.111.174474"}},"subtitle":["The Delapril and Manidipine for Nephroprotection in Diabetes (DEMAND) Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["10.1161\/HYPERTENSIONAHA.111.174474"],"URL":"https:\/\/doi.org\/10.1161\/hypertensionaha.111.174474","relation":{},"ISSN":["0194-911X","1524-4563"],"issn-type":[{"value":"0194-911X","type":"print"},{"value":"1524-4563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,11]]},"assertion":[{"value":"2011-04-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2011-08-25","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2011-09-19","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}